- Home
- IGMS
IGMS
IGM Biosciences Inc.
as 07-26-2024 4:00pm EST
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
Upcoming Earnings Alert:
Get ready for potential market movements as IGM Biosciences Inc. IGMS prepares to release earnings report on 01 Aug 2024.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | MOUNTAIN VIEW |
| Market Cap: | 592.9M | IPO Year: | 2019 |
| Target Price: | $17.00 | AVG Volume (30 days): | 426.8K |
| Analyst Decision: | Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.28 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.81 - $17.70 | Next Earning Date: | 08-01-2024 |
| Revenue: | $2,105,000 | Revenue Growth: | 32.31% |
| Revenue Growth (this year): | 2092.54% | Revenue Growth (next year): | -77.23% |
Stock Insider Trading Activity of IGM Biosciences Inc. (IGMS)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Decker Lisa Lynn | IGMS | CHIEF BUSINESS OFFICER | Jun 14 '24 | Sell | $7.58 | 977 | $7,401.07 | 60,029 | SEC Form 4 |
| Takimoto Chris H | IGMS | CHIEF MEDICAL OFFICER | Jun 14 '24 | Sell | $7.58 | 1,570 | $11,893.22 | 95,818 | SEC Form 4 |
| Schwarzer Fred | IGMS | CEO AND PRESIDENT | Jun 14 '24 | Sell | $7.58 | 4,164 | $31,543.55 | 254,070 | SEC Form 4 |
| Keyt Bruce | IGMS | CHIEF SCIENTIFIC OFFICER | Jun 14 '24 | Sell | $7.58 | 1,106 | $8,378.28 | 197,769 | SEC Form 4 |
| Weber Steven | IGMS | PRINCIPAL ACCOUNTING OFFICER | Jun 14 '24 | Sell | $7.58 | 495 | $3,749.77 | 26,012 | SEC Form 4 |
| Tahir Misbah | IGMS | CHIEF FINANCIAL OFFICER | Jun 14 '24 | Sell | $7.58 | 1,570 | $11,893.22 | 88,848 | SEC Form 4 |
| BAKER BROS. ADVISORS LP | IGMS | Director10% Owner | Mar 26 '24 | Buy | $8.26 | 22,344 | $184,608.36 | 336,796 | SEC Form 4 |
| BAKER BROS. ADVISORS LP | IGMS | Director10% Owner | Mar 26 '24 | Buy | $8.26 | 247,656 | $2,046,158.64 | 3,638,533 | SEC Form 4 |
| BAKER BROS. ADVISORS LP | IGMS | Director10% Owner | Mar 26 '24 | Buy | $9.22 | 1,543 | $14,227.54 | 338,339 | SEC Form 4 |
| BAKER BROS. ADVISORS LP | IGMS | Director10% Owner | Mar 26 '24 | Buy | $9.22 | 17,101 | $157,683.19 | 3,655,634 | SEC Form 4 |
| BAKER BROS. ADVISORS LP | IGMS | Director10% Owner | Mar 26 '24 | Buy | $9.27 | 761 | $7,052.42 | 339,100 | SEC Form 4 |
| BAKER BROS. ADVISORS LP | IGMS | Director10% Owner | Mar 26 '24 | Buy | $9.27 | 8,439 | $78,206.74 | 3,664,073 | SEC Form 4 |
| BAKER BROS. ADVISORS LP | IGMS | Director10% Owner | Mar 26 '24 | Buy | $9.62 | 8,066 | $77,590.08 | 347,166 | SEC Form 4 |
| BAKER BROS. ADVISORS LP | IGMS | Director10% Owner | Mar 26 '24 | Buy | $9.62 | 89,407 | $860,041.70 | 3,753,480 | SEC Form 4 |
| Weber Steven | IGMS | PRINCIPAL ACCOUNTING OFFICER | Mar 13 '24 | Sell | $9.88 | 529 | $5,223.98 | 26,971 | SEC Form 4 |
| Weber Steven | IGMS | PRINCIPAL ACCOUNTING OFFICER | Mar 13 '24 | Sell | $10.17 | 464 | $4,719.11 | 26,507 | SEC Form 4 |
| Keyt Bruce | IGMS | CHIEF SCIENTIFIC OFFICER | Mar 13 '24 | Sell | $9.88 | 2,101 | $20,747.80 | 173,700 | SEC Form 4 |
| Keyt Bruce | IGMS | CHIEF SCIENTIFIC OFFICER | Mar 13 '24 | Sell | $10.17 | 1,844 | $18,754.40 | 171,856 | SEC Form 4 |
| Tahir Misbah | IGMS | CHIEF FINANCIAL OFFICER | Mar 13 '24 | Sell | $9.88 | 2,897 | $28,608.45 | 92,961 | SEC Form 4 |
| Tahir Misbah | IGMS | CHIEF FINANCIAL OFFICER | Mar 13 '24 | Sell | $10.17 | 2,543 | $25,863.58 | 90,418 | SEC Form 4 |
| Schwarzer Fred | IGMS | CEO AND PRESIDENT | Mar 13 '24 | Sell | $9.88 | 4,765 | $47,055.33 | 220,833 | SEC Form 4 |
| Schwarzer Fred | IGMS | CEO AND PRESIDENT | Mar 13 '24 | Sell | $10.17 | 4,182 | $42,533.03 | 216,651 | SEC Form 4 |
| Takimoto Chris H | IGMS | CHIEF MEDICAL OFFICER | Mar 13 '24 | Sell | $9.88 | 2,889 | $28,529.45 | 96,923 | SEC Form 4 |
| Takimoto Chris H | IGMS | CHIEF MEDICAL OFFICER | Mar 13 '24 | Sell | $10.17 | 2,535 | $25,782.22 | 94,388 | SEC Form 4 |
| Decker Lisa Lynn | IGMS | CHIEF BUSINESS OFFICER | Mar 13 '24 | Sell | $9.88 | 1,798 | $17,755.61 | 62,584 | SEC Form 4 |
Latest IGM Biosciences Inc. News
IGMS Breaking Stock News: Dive into IGMS Ticker-Specific Updates for Smart Investing
Zacks
14 days ago
IGM Biosciences (IGMS) Soars 32.7%: Is Further Upside Left in the Stock?
GOBankingRates
2 months ago
5 Reasons a Biden Second Term Could Be a Financial Disaster for Boomers
AFP
2 months ago
Bumrah delivers as India beat Pakistan in low-scoring thriller
AFP
2 months ago
Italy beat Bosnia in final Euros warm-up
AFP
2 months ago
Trump loyalists proud to support 'felon' at Las Vegas rally
Business Insider
2 months ago
US solar producers could finally have a fighting chance as tariffs kick in on cheaper imports from Asia
Insider Monkey
2 months ago
The Best Woody Perfume For Women
Reuters
2 months ago
Microsoft unveils all-digital Xbox consoles, 'Doom' title at Games Showcase
Compare IGMS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IGMS IGM Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.